FDA Approves Merck’s WINREVAIR™ (sotatercept-csrk), a First-in-Class Treatment for Adults with Pulmonary Arterial Hypertension (PAH, WHO* Group 1)
Merck (MRK) receives FDA approval for WINREVAIR, a breakthrough therapy for pulmonary arterial hypertension (PAH), showing significant clinical benefits in improving exercise capacity and reducing clinical worsening events. WINREVAIR is the first FDA-approved activin signaling inhibitor therapy for PAH, offering a new treatment pathway.
The FDA approval of WINREVAIR, a new biologic therapy for pulmonary arterial hypertension (PAH), marks a significant advancement in the treatment landscape for this condition. The financial implications for Merck, as the manufacturer, are potentially substantial given the rarity and severity of PAH and the lack of diverse treatment options. This novel activin signaling inhibitor therapy represents a new approach to managing a disease that has historically had limited therapeutic advancements.
From an investor's perspective, the approval could translate into a competitive edge for Merck in the specialty biologics market. The breakthrough therapy designation previously granted by the FDA likely expedited the development and review process, which can be advantageous in terms of cost-savings and achieving market penetration more rapidly. However, the long-term financial impact will depend on the drug's adoption rate, pricing strategy, insurance coverage and the actual benefit to patients in a real-world setting.
It is also important to consider the potential risks associated with the drug, such as the need for monitoring hemoglobin and platelets, which could affect patient compliance and overall market uptake. Furthermore, the safety profile and the risk of thromboembolic events or hyperviscosity syndrome highlighted in the safety information are important factors that healthcare providers will weigh when considering this treatment for their patients.
The introduction of WINREVAIR into the market presents an opportunity for Merck to tap into a niche yet underserved medical need. Given the rarity of PAH, the patient population is relatively small, which typically leads to higher drug prices under orphan drug designations. The approval based on the STELLAR trial results, which showed a significant improvement in exercise capacity and reduction in clinical worsening events, positions WINREVAIR as a strong entrant into the PAH treatment market.
Market adoption will likely be influenced by the drug's efficacy in comparison to existing therapies, its side effect profile and the convenience of subcutaneous administration every three weeks. The latter could be particularly appealing to patients and caregivers looking for more manageable treatment regimens. The ability to self-administer may also reduce the overall cost of care, an important consideration for payers when deciding on coverage policies.
Merck's strategy to make WINREVAIR available through select specialty pharmacies could streamline distribution and ensure that patients receive adequate support and education. This specialized approach to dispensing may also enhance patient adherence and outcomes, further justifying the drug's value proposition in a market that prioritizes demonstrable health benefits and cost-effectiveness.
The clinical significance of WINREVAIR's approval extends beyond its immediate therapeutic benefits. As the first FDA-approved activin signaling inhibitor for PAH, it opens new avenues for research into the pathophysiology of the disease. The drug's mechanism, which involves regulating vascular cell proliferation, offers a fresh perspective on targeting the underlying causes of PAH rather than just managing its symptoms.
Long-term, the success of WINREVAIR will likely be measured not only by its market performance but also by its impact on patient outcomes and quality of life. The reduction in risk of death from any cause or PAH clinical worsening events by 84% is a remarkable clinical achievement, but real-world evidence will be important to validate these findings. Post-marketing surveillance and further studies will be essential to monitor the long-term safety and effectiveness of the drug, as well as to explore potential uses in other conditions characterized by vascular proliferation.
The specificity of the drug's indications and the requirement for pre-dosing monitoring suggest that Merck will need to work closely with healthcare providers to ensure that the drug's benefits are maximized and risks are minimized. This includes educating providers on the importance of patient selection and monitoring, which can be resource-intensive but is necessary for achieving the best patient outcomes.
03/26/2024 - 06:21 PM
WINREVAIR is a breakthrough biologic for this rare, progressive disease
WINREVAIR on top of background therapy significantly improved exercise capacity and multiple important secondary outcome measures compared to background therapy alone
RAHWAY, N.J. --(BUSINESS WIRE)--
Merck (NYSE: MRK), known as MSD outside of the United States and Canada , announced today that the U.S. Food and Drug Administration (FDA) has approved sotatercept-csrk (U.S. Brand Name: WINREVAIR™, for injection, 45mg, 60mg) for the treatment of adults with pulmonary arterial hypertension (PAH, World Health Organization [WHO] Group 1) to increase exercise capacity, improve WHO functional class (FC), and reduce the risk of clinical worsening events. WINREVAIR was previously granted Breakthrough Therapy Designation by the FDA. WINREVAIR is the first FDA-approved activin signaling inhibitor therapy for PAH, representing a new class of therapy that works by improving the balance between pro- and anti-proliferative signaling to regulate vascular cell proliferation underlying PAH.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240326077272/en/
WINREVAIR logo (Graphic: Merck & Co., Inc.)
“Pulmonary arterial hypertension is a rare, progressive and ultimately life-threatening disease in which blood vessels in the lungs thicken and narrow, causing significant strain on the heart,” said Dr. Marc Humbert, Professor of Medicine and Director of the Pulmonary Hypertension Reference Center at the Université Paris-Saclay and investigator on the Phase 3 STELLAR study. “Based on the Phase 3 STELLAR trial, adding WINREVAIR to background PAH therapy demonstrated significant clinical benefits compared to background PAH therapy alone. This approval is an important milestone, as it offers healthcare providers a novel therapeutic option that targets a new PAH treatment pathway.”
The approval is based on the Phase 3 STELLAR trial, which compared WINREVAIR (n=163) to placebo (n=160), both in combination with background standard of care therapies in adult patients with PAH (WHO Group 1 FC II or III). Results showed adding WINREVAIR to background therapy increased six-minute walk distance from baseline by 41 meters (95% CI: 28, 54; p<0.001; placebo-adjusted) at Week 24 and significantly improved multiple important secondary outcome measures, including reducing the risk of death from any cause or PAH clinical worsening events by 84% versus background therapy alone (number of events: 9 vs 42, hazard ratio=0.16; 95% CI: 0.08, 0.35; p<0.001).
Healthcare providers should monitor hemoglobin and platelets before each dose of WINREVAIR for the first 5 doses, or longer if values are unstable, and periodically thereafter to determine if dose adjustments are required. WINREVAIR may increase hemoglobin and may lead to erythrocytosis, which if severe may increase the risk of thromboembolic events or hyperviscosity syndrome. WINREVAIR also may decrease platelet count and lead to severe thrombocytopenia, which may increase the risk of bleeding; thrombocytopenia occurred more frequently in patients also receiving prostacyclin infusion. Treatment should not be initiated if platelet count is <50,000/mm3 . See additional Selected Safety Information below.
“The Pulmonary Hypertension Association welcomes the development of new therapies for those with PAH,” said Matt Granato, president and chief executive officer, Pulmonary Hypertension Association. “A diagnosis of PAH is a life-changing experience for patients and families due to its chronic, progressive nature. Patients with PAH experience limiting symptoms such as shortness of breath and fatigue. We are excited to see industry research leading to a better understanding of PAH and the development of a medicine in a novel treatment pathway that expands options for the patient community.”
“New treatment options continue to be needed for patients with pulmonary arterial hypertension that support important clinical goals, including increasing exercise capacity and improving functional class,” said Dr. Aaron Waxman, Executive Director of the Center for Pulmonary Heart Diseases at Brigham and Women’s Hospital and investigator on the Phase 3 STELLAR study. “Sotatercept added to background therapy has the potential to become a new standard of care option for patients with pulmonary arterial hypertension.”
WINREVAIR is given once every three weeks by subcutaneous injection and may be administered by appropriate patients or caregivers with guidance, training and follow-up from a healthcare provider. Healthcare providers and patients/caregivers should refer to the Instructions for Use for information on the proper preparation and administration of WINREVAIR. Merck estimates that WINREVAIR will be available for dispensing by select specialty pharmacies in the U.S. by the end of April.
“PAH remains a debilitating disease with high morbidity and mortality,” said Dr. Eliav Barr, senior vice president and head of global clinical development, chief medical officer, Merck Research Laboratories. “This approval of WINREVAIR is an important milestone and a testament to our science-led strategy and focus on the development of innovations that can help people affected by rare diseases like PAH. We are proud to bring this novel medicine to patients.”
Merck offers support to patients who are prescribed WINREVAIR, including information about insurance coverage and help for eligible patients with out-of-pocket costs and co-pay assistance options, through the Merck Access Program. For additional information, healthcare providers and patients can call 1-888-637-2502 or visit www.merckaccessprogram-WINREVAIR.com in the coming days.
STELLAR Study Results
The primary efficacy endpoint in the STELLAR trial was the change from baseline at Week 24 in 6-Minute Walk Distance (6MWD). In the WINREVAIR treatment group, the placebo-adjusted median increase in 6MWD was 41 meters (95% CI: 28, 54; p<0.001, Hodges-Lehmann estimate). Additionally, patients who added WINREVAIR had statistically significantly greater improvements compared to placebo across multiple secondary endpoints:
Treatment with WINREVAIR led to an improvement in FC from baseline at Week 24 in 29% of patients compared to 14% of patients treated with placebo (p<0.001).
Treatment with WINREVAIR resulted in an 84% reduction in the occurrence of death or PAH clinical worsening events compared to placebo (median duration of exposure 33.6 weeks; number of events: 9/163 vs 42/160, hazard ratio=0.16; 95% CI: 0.08, 0.35; p<0.001).
Treatment with WINREVAIR led to an improvement from baseline in pulmonary vascular resistance (PVR). The median treatment difference in PVR between WINREVAIR and placebo was -235 dynes*sec/cm5 (95% CI: -288, -181; p<0.001).
Treatment with WINREVAIR led to an improvement from baseline in N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels. The median treatment difference in NT-proBNP between WINREVAIR and placebo was -442 pg/mL (95% CI: -574, -310; p<0.001).
About STELLAR
The STELLAR study (NCT04576988) was a global, double-blind, placebo-controlled, multicenter, parallel-group clinical trial in which 323 patients with PAH (WHO Group 1 FC II or III) were randomized 1:1 to WINREVAIR (target dose 0.7 mg/kg) (n=163) or placebo (n=160) plus stable background therapy administered subcutaneously once every 3 weeks.
The most common PAH etiologies were idiopathic PAH (59% ), heritable PAH (18% ), and PAH associated with connective tissue diseases (CTD) (15% ). Most participants were receiving either three (61% ) or two (35% ) background drugs for PAH, and 40% were receiving prostacyclin infusions. The mean time from PAH diagnosis was 8.8 years. Patients had a WHO FC II (49% ) or III (51% ) at baseline.
About WINREVAIR™ (sotatercept-csrk) for injection, for subcutaneous use, 45 mg, 60 mg
WINREVAIR is FDA-approved for the treatment of adults with pulmonary arterial hypertension (PAH, WHO Group 1) to increase exercise capacity, improve WHO functional class (FC) and reduce the risk of clinical worsening events. WINREVAIR is the first activin signaling inhibitor therapy approved to treat PAH. WINREVAIR improves the balance between pro-proliferative and anti-proliferative signaling to modulate vascular proliferation. In preclinical models, WINREVAIR induced cellular changes that were associated with thinner vessel walls, partial reversal of right ventricular remodeling, and improved hemodynamics.
WINREVAIR is the subject of a licensing agreement with Bristol Myers Squibb.
Selected Safety Information
WINREVAIR may increase hemoglobin and may lead to erythrocytosis. Severe erythrocytosis may increase the risk of thromboembolic events or hyperviscosity syndrome. Monitor Hgb before each dose for the first 5 doses, or longer if values are unstable, and periodically thereafter, to determine if dose adjustments are required.
WINREVAIR may decrease platelet count and lead to severe thrombocytopenia, which may increase the risk of bleeding; thrombocytopenia occurred more frequently in patients also receiving prostacyclin infusion. Do not initiate treatment if platelet count is <50,000/mm3 . Monitor platelets before each dose for the first 5 doses, or longer if values are unstable, and periodically thereafter to determine if dose adjustments are required.
In clinical studies, serious bleeding (e.g., gastrointestinal, intracranial hemorrhage)
was reported in 4% of patients taking WINREVAIR and 1% of patients taking placebo. Serious bleeding was more likely in patients on prostacyclin background therapy and/or antithrombotic agents, or with low platelet counts. Advise patients about signs and symptoms of blood loss. Do not administer WINREVAIR if the patient is experiencing serious bleeding.
WINREVAIR may cause fetal harm when administered to a pregnant woman. Advise pregnant women of the potential risk to a fetus. Advise females of reproductive potential to use an effective method of contraception during treatment with WINREVAIR and for at least 4 months after the final dose. Pregnancy testing is recommended for females of reproductive potential before starting WINREVAIR treatment.
Based on findings in animals, WINREVAIR may impair female and male fertility. Advise patients on the potential effects on fertility.
The most common adverse reactions occurring in the Phase 3 clinical trial (≥10% for WINREVAIR and at least 5% more than placebo) were headache (24.5% vs 17.5% ), epistaxis (22.1% vs 1.9% ), rash (20.2% vs 8.1% ), telangiectasia (16.6% vs 4.4% ), diarrhea (15.3% vs 10.0% ), dizziness (14.7% vs 6.2% ), and erythema (13.5% vs 3.1% ).
Because of the potential for serious adverse reactions in the breastfed child, advise patients that breastfeeding is not recommended during treatment with WINREVAIR, and for 4 months after the final dose.
About Merck
At Merck, known as MSD outside of the United States and Canada , we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than 130 years, we have brought hope to humanity through the development of important medicines and vaccines. We aspire to be the premier research-intensive biopharmaceutical company in the world – and today, we are at the forefront of research to deliver innovative health solutions that advance the prevention and treatment of diseases in people and animals. We foster a diverse and inclusive global workforce and operate responsibly every day to enable a safe, sustainable and healthy future for all people and communities. For more information, visit www.merck.com and connect with us on X (formerly Twitter), Facebook , Instagram , YouTube and LinkedIn .
Forward-Looking Statement of Merck & Co., Inc., Rahway, N.J. , USA
This news release of Merck & Co., Inc., Rahway, N.J. , USA (the “company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company’s management and are subject to significant risks and uncertainties. There can be no guarantees with respect to pipeline candidates that the candidates will receive the necessary regulatory approvals or that they will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.
Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.
The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company’s Annual Report on Form 10-K for the year ended December 31, 2023 and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site (www.sec.gov ).
Please see Prescribing Information for WINREVAIR (sotatercept-csrk) at http://www.merck.com/product/usa/pi_circulars/w/winrevair/winrevair_pi.pdf , Patient Information for WINREVAIR at http://www.merck.com/product/usa/pi_circulars/w/winrevair/winrevair_ppi.pdf , and Instructions for Use for WINREVAIR (1-vial kit, 2-vial kit) at https://www.merck.com/product/usa/pi_circulars/w/winrevair/winrevair_ifu_1-vial_2-vial_kits.pdf .
*WHO = World Health Organization
View source version on businesswire.com: https://www.businesswire.com/news/home/20240326077272/en/
Media Contacts:
Julie Cunningham
Investor Contacts:
Peter Dannenbaum
Source: Merck & Co., Inc.
What is the U.S. Brand Name for sotatercept-csrk approved by the FDA for PAH treatment?
The U.S. Brand Name for sotatercept-csrk approved by the FDA for PAH treatment is WINREVAIR.
What is the WHO group classification for PAH?
PAH belongs to World Health Organization (WHO) Group 1.
What are the key benefits of adding WINREVAIR to background PAH therapy according to the Phase 3 STELLAR trial?
Adding WINREVAIR to background PAH therapy significantly increased six-minute walk distance and reduced the risk of death or PAH clinical worsening events by 84% compared to background therapy alone.
How often is WINREVAIR administered and through which route?
WINREVAIR is given once every three weeks by subcutaneous injection.
When will WINREVAIR be available for dispensing in the U.S.?
Merck estimates that WINREVAIR will be available for dispensing by select specialty pharmacies in the U.S. by the end of April.
